Photo: Welcome speech to all selected Stanford Impact1 companies at the Pediatric MedTech CEO Summit by Dr. Janene H. Fuerch, Co-Director of Impact1, MD, and Assistant Professor of Neonatology at Stanford University Medical Center
CEO Hanna Sjöström had the privilege of representing Neola Medical at this year’s Pediatric MedTech CEO Summit, a highly regarded forum established by the prestigious Stanford Impact1 CEO program. Hosted by CobiCure in New York, the summit convened an exclusive network of MedTech entrepreneurs, investors, leading U.S. pediatric experts and representatives from the Pediatric team at the FDA. This influential gathering fostered invaluable discussions and collaborations aimed at driving innovation in pediatric healthcare, perfectly aligning with Neola Medical’s vision to transform neonatal care.
Attending the Pediatric MedTech CEO Summit by Stanford Impact1 in New York provided an exceptional opportunity to connect with global leaders in medical technology. Being part of this exclusive network of MedTech entrepreneurs, investors, and leading pediatric and neonatology specialists was invaluable. It was truly inspiring to see our vision for transforming neonatal intensive care resonate with such influential key opinion leaders, who recognized the critical role Neola® could play in improving outcomes for preterm born babies.
– CEO Hanna Sjöström
The Pediatric MedTech CEO Summit serves as a unique platform where top innovators in medical technology unite to explore transformative solutions for improving the health, safety, and quality of life of pediatric and maternal patients. For Neola Medical, participation in such a distinguished forum underscores our commitment to advancing groundbreaking technologies that can redefine the standard of care for preterm born infants and improve clinical outcomes of this vulnerable patient group.
Neola Medical’s involvement with Stanford Impact1 started last year when we were honored to be one of just a few MedTech companies selected as a Stanford Impact1 company for this prestigious program. Neola®, our advanced medical device for continuous lung monitoring, was recognized by Stanford’s neonatology experts as a revolutionary innovation with the potential to redefine neonatal intensive care from day one it reaches the clinic. The Stanford Impact1 program is dedicated to accelerating innovations that enhance the health, safety, and quality of life of pediatric and maternal patients globally.
→ Read the press release about the Stanford Impact1 program announcement here: Neola Medical selected as a Stanford Impact1 Company
→ Watch the welcome speech to the Stanford Impact1 program by founding director, James Wall, here: Welcome to Stanford Impact1
About Stanford Impact1 program
Each year, the US Food and Drug Administration (FDA) approves far fewer health technologies for use in children than adults. This means that pediatric specialists do not always have access to the advanced tools they need to address the unique healthcare needs of their small, vulnerable patients. Stanford launched Impact1 to improve the health, safety, and quality of life of pediatric patients and pregnant women in order to accelerate the development and availability of high-value, high-impact pediatric health technologies. The program leverages Stanford Biodesign’s need-driven innovation process to accomplish this goal. It benefits from access to world-renowned clinicians and engineers at Stanford, as well as an unparalleled network of Silicon Valley experts in medical device product development, regulatory affairs, intellectual property, reimbursement, and commercialization. Learn more here: Impact1 by Stanford Biodesign